Marginal Zone Lymphoma
📧 Sign up to get email alerts when something new happens for Marginal Zone Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-05-24Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial evaluating a multi-modality approach combining Yttrium-90 ibritumomab tiuxetan, fludarabine, radiation therapy, and d…
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma [Phase 2]
Phase 2 study evaluating rituximab plus dexamethasone in patients with low-grade non-Hodgkin lymphoma, including follicular and marginal zon…
-
CLINICAL_TRIALS withdrawal · 2017-05-19Clinical Trial Update: Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 2]
The Phase 2 trial of Brentuximab Vedotin, Bendamustine, and Rituximab for relapsed or refractory B-cell non-Hodgkin lymphoma has been withdr…
-
CLINICAL_TRIALS trial_result · 2017-05-12Clinical Trial Update: Safety and Tolerability of HSC835 in Patients With Hematological Malignancies [Phase 1, Phase 2]
Phase 1/2 trial assessing safety and tolerability of HSC835 in patients with various hematologic malignancies completed with results posted …
-
CLINICAL_TRIALS trial_result · 2017-05-08Clinical Trial Update: Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial of oral clofarabine in relapsed/refractory non-Hodgkin lymphoma completed with posted results.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-03-17Clinical Trial Update: Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma [Phase 2]
A Phase 2 study evaluating ofatumumab as initial systemic therapy for indolent B-cell lymphomas has completed, with results posted in March …
-
CLINICAL_TRIALS trial_result · 2017-02-10Clinical Trial Update: Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma [Phase 2]
Phase 2 trial update for a Bruton's Tyrosine Kinase inhibitor in relapsed/refractory marginal zone lymphoma and B-cell lymphoma has complete…
-
CLINICAL_TRIALS trial_result · 2016-12-21Clinical Trial Update: Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma [Phase 1, Phase 2]
Clinical trial update for idelalisib (GS-1101) in previously treated indolent non-Hodgkin's lymphoma, including follicular lymphoma, reporti…
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: Gemcitabine for Marginal Zone Lymphoma [Phase 2]
A Phase 2 trial evaluating gemcitabine for marginal zone lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2016-02-15Clinical Trial Update: A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) [Phase 2]
Phase 2 pilot trial of oral vorinostat plus eltrombopag in lymphoma was terminated.
-
CLINICAL_TRIALS trial_result · 2016-01-01Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma [Phase 2]
Phase 2 trial evaluating Yttrium-90 ibritumomab tiuxetan with rituximab for previously untreated marginal zone lymphoma; the study is comple…
-
CLINICAL_TRIALS trial_result · 2015-12-17Clinical Trial Update: Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a radiolabeled monoclonal antibody with rituximab, with/without filgrastim and interleukin-11, in relapsed or r…
-
CLINICAL_TRIALS trial_result · 2015-12-04Clinical Trial Update: Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial of obatoclax with bortezomib in adults with aggressive relapsed or recurrent non-Hodgkin lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2015-11-26Clinical Trial Update: Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial of lenalidomide plus rituximab as maintenance therapy for adult B-cell non-Hodgkin lymphoma is noted as terminated.
-
CLINICAL_TRIALS trial_result · 2015-10-19Clinical Trial Update: Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma [Phase 1]
Phase 1 study of GS-9901 in adults with relapsed or refractory follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, or…
-
CLINICAL_TRIALS trial_result · 2015-05-07Clinical Trial Update: Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma [Phase 2]
Phase 2 trial evaluating epigenetic modulation in relapsed/refractory follicular lymphoma and marginal zone lymphoma was terminated, with re…
-
CLINICAL_TRIALS trial_result · 2015-02-18Clinical Trial Update: Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial evaluating Rituximab with chemotherapy and 90-yttrium ibritumomab tiuxetan in patients with Stage I or II non-Hodgkin lympho…
-
CLINICAL_TRIALS trial_result · 2014-11-07Clinical Trial Update: RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors [Phase 1]
Phase 1 trial evaluating RO4929097 in combination with capecitabine in patients with refractory solid tumors has completed.
-
CLINICAL_TRIALS trial_result · 2014-11-04Clinical Trial Update: Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL) [Phase 2]
Phase 2 trial evaluating oxaliplatin plus prednisolone (Ox-P) in patients with relapsed or refractory marginal zone lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2014-10-06Clinical Trial Update: Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma [Phase 2]
This Phase 2 trial evaluated the combination of fludarabine and rituximab for marginal zone non-Hodgkin's lymphoma (MALT lymphoma) and has c…
-
CLINICAL_TRIALS trial_result · 2014-09-04Clinical Trial Update: Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 trial assessing idelalisib for indolent B-cell non-Hodgkin lymphomas completed with results posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-09-01Clinical Trial Update: Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating agatolimod sodium in combination with rituximab and Yttrium-90 ibritumomab tiuxetan for adults with re…
-
CLINICAL_TRIALS trial_result · 2014-08-27Clinical Trial Update: Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia [Phase 1]
Phase 1 trial of vorinostat combined with decitabine in adults with advanced solid tumors or relapsed/refractory hematologic cancers, includ…
-
CLINICAL_TRIALS trial_result · 2014-07-01Clinical Trial Update: Imexon for Relapsed Follicular and Aggressive Lymphomas [Phase 2]
Phase 2 clinical trial results for imexon in relapsed follicular lymphoma and various aggressive B-cell lymphomas have been completed with r…
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 trial evaluating bortezomib and fludarabine with or without rituximab in relapsed or refractory indolent non-Hodgkin lymphoma or chr…